These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 6405544)

  • 21. Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy.
    Blumenthal RD; Lew W; Juweid M; Alisauskas R; Ying Z; Goldenberg DM
    Cancer; 2000 Jan; 88(2):333-43. PubMed ID: 10640965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Blood component replacement in bone marrow aplasia in patients after aggressive chemotherapy for malignant hematologic diseases].
    Kubesová H; Krahulcová E; Kiss I; Vorlícek J
    Vnitr Lek; 1993 May; 39(5):430-6. PubMed ID: 8351873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours.
    Nowrousian MR
    Med Oncol; 1998 Aug; 15 Suppl 1():S19-28. PubMed ID: 9785333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
    Hofland KF; Thougaard AV; Sehested M; Jensen PB
    Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prevention and treatment of chemotherapy-induced digestive toxicities].
    Boige V; Ducreux M
    Bull Cancer; 2001 Feb; 88(2):163-73. PubMed ID: 11257591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients.
    Kayl AE; Meyers CA
    Curr Opin Obstet Gynecol; 2006 Feb; 18(1):24-8. PubMed ID: 16493256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managing hematologic toxicities.
    Capo G; Waltzman R
    J Support Oncol; 2004; 2(1):65-79. PubMed ID: 15330374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changing patient perceptions of the side effects of cancer chemotherapy.
    Carelle N; Piotto E; Bellanger A; Germanaud J; Thuillier A; Khayat D
    Cancer; 2002 Jul; 95(1):155-63. PubMed ID: 12115329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EPO in cancer anemia: benefits and potential risks.
    Milano M; Schneider M
    Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preventing chemotherapy-induced alopecia.
    Smith FP; McCabe MS
    Am Fam Physician; 1983 Jul; 28(1):182-4. PubMed ID: 6869167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Standards, Options, and Recommendations for using erythropoietin in cancerology].
    Spaëth D; Marchal C; Blanc-Vincent MP
    Bull Cancer; 1998 Apr; 85(4):337-46. PubMed ID: 9752298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
    Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
    Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
    Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Leukopenia and thrombopenia induced by chemotherapy].
    Nieweg R; van Rijswijk R
    TVZ; 1992 Jan; (2):53-5. PubMed ID: 1540322
    [No Abstract]   [Full Text] [Related]  

  • 38. [Toxic lesions caused by cytostatic drugs].
    Gropp C; Havemann K
    Internist (Berl); 1980 Dec; 21(12):739-45. PubMed ID: 7009476
    [No Abstract]   [Full Text] [Related]  

  • 39. Managing chemotherapy-induced bone marrow suppression in cancer.
    Lokich JJ
    Hosp Pract; 1976 Aug; 11(8):61-7. PubMed ID: 1027711
    [No Abstract]   [Full Text] [Related]  

  • 40. [Results in the use of blood components separated by cytophoresis in leukemia treated with cytostatics (our 1st experiences with flowing-effect centrifuge)].
    Bosković S; Haracić M
    Bilt Hematol Transfuz; 1976; 4(1-2):97-104. PubMed ID: 942368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.